A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer

摘要

In this study we assessed the efficacy/safety of rilotumumab or ganitumab with chemotherapy as first-line treatment in small-cell lung cancer. Patients received rilotumumab or ganitumab with chemotherapy (phase 1b, n = 28), or were randomized to receive placebo, rilotumumab, or ganitumab with chemotherapy (phase 2, n = 185). One patient treated with ganitumab experienced a dose-limiting toxicity. No significant differences in outcomes were observed between treatments.